Long-term effects of early administered sildenafil and NO donor on the cardiovascular system of SHR

Journal of Physiology and Pharmacology

Volumn 58, Issue 1, 2007, Pages 33-43

  Kristek, František ^a   Koprdova R ^a   Cebova M ^a  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Circumferential stress; Geometry; Hypertension; Nitric oxide donor; Pentaerythrityl tetranitrate; Sildenafil

Indexed keywords

PENTAERYTHRITYL TETRANITRATE; SILDENAFIL; ANTIHYPERTENSIVE AGENT; NITRIC OXIDE DONOR; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE; VASODILATOR AGENT;

ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; CAROTID ARTERY; CONTROLLED STUDY; CORONARY ARTERY; DRUG EFFECT; ELECTRON MICROSCOPY; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; MICROSCOPY; NONHUMAN; PLETHYSMOGRAPHY; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; ANIMAL; BLOOD PRESSURE; CARDIOMEGALY; CARDIOVASCULAR SYSTEM; CORONARY BLOOD VESSEL; DISEASE COURSE; DISEASE MODEL; DRUG ADMINISTRATION; DRUG COMBINATION; PATHOLOGY; PATHOPHYSIOLOGY; TIME; WISTAR RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOMEGALY; CARDIOVASCULAR SYSTEM; CAROTID ARTERIES; CORONARY VESSELS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HYPERTENSION; NITRIC OXIDE DONORS; PENTAERYTHRITOL TETRANITRATE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; RATS; RATS, INBRED SHR; RATS, WISTAR; SULFONES; TIME FACTORS; VASODILATOR AGENTS;

EID: 34248232967     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Lüscher TF. The endothelium: Target and promoter of hypertension? Hypertension 1990; 15: 482-485.
2. Arnal JF, Battle T, Menard J, Michel JB. The vasodilatory effect of endogenous nitric oxide is a major counter-regulatory mechanism in the spontaneously hypertensive rat. J Hypertens 1993; 11: 945-950.
3. Malinski T, Kapturczak M, Dayharsch J, Bohr D. Nitric oxide synthase activity in genetic hypertension. Biochem Biophys Res Commun 1993; 194: 654-568.
4. Gerová M. Nitric oxide-compromised hypertension: Facts and enigmas. Physiol Res 2000; 49: 17-35.
5. Kristek F. Long-term administration of L-arginine did not influence blood pressure, heart rate, cardiac hypertrophy or arterial wall thickness of spontaneously hypertensive rats. Exp Physiol 1998; 83: 595-603.
6. Kristek F. Pentaerythrityl tetranitrate attenuates structural changes in conduit arteries evoked by long-term NO-synthase inhibition. Brit J Pharmacol 2000; 130: 450-456.
7. Török J, Kristek F. Beneficial effect of pentaerythrityl tetranitrate on functional and morphological changes in the rat thoracic aorta evoked by long-term nitric oxide synthase inhibition. Vasc Pharmacol 2002; 38: 177-182.
8. Kristek F, Fáberová V, Varga I. Long-term effect of molsidomine and pentaerythrityl tetranitrate on cardiovascular system of spontaneously hypertensive rats. Physiol Res 2003; 52: 709-717.
9. Tucker EJ, Ledingham JM, Zheng Y, Laverty R. Effects of chronic inhibition of nitric oxide synthase in the genetically hypertensive rat. Clin Exp Pharmacol Physiol 2000; 27: 647-649.
10. Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998; 159: 2164-2171.
11. Sakuma I, Akaishi Y, Tomioka H, Sato A, Kitabatake A, Hattori Y. Interactions of sildenafil with various coronary vasodilators in isolated porcine coronary artery. Eur J Pharmacol 2002; 437: 155-163.
12. Raja SG, Nayak SH. Sildenafil: Emerging cardiovascular indications. Ann Thorac Surg 2004; 78: 1496-1506.
13. Kloner RA. Cardiovascular risk and sildenafil. Am J Cardiol 2000; 86: 57F-61F.
14. Brindis RG, Kloner RA. Sildenafil in patients with cardiovascular disease. Am J Cardiol 2003; 92: 26M-36M.
15. Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and haemodynamic in patients with pulmonary arterial hypertension. Circulation 2003; 108: 2066-2069.
16. Preston IR, Hill NS, Gambardella LS, Warburton RR, Klinger JR. Synergistic effects of ANP and sildenafil on cGMP levels and amelioration of acute hypoxic pulmonary hypertension. Exp Biol Med 2004; 229: 920-925.
17. Jackson G, Keltai M, Csanady M, et al. Hemodynamic effects of sildenafil citrate and isosorbide mononitrate in men with coronary artery disease and erectile dysfunction. J Sex Med 2005; 2: 407-414.
18. Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats. Jap Circ J 1963; 27: 282-293.
19. Urminská M, Kristek F. Structure of coronary artery of SHR in prehypertensive and early hypertensive period of ontogenic development [abstract]. Physiol Res 2004; 53: 41P.
20. Lee RMKV. Vascular changes at the prehypertensive phase in the mesenteric arteries from spontaneously hypertensive rats. Blood Vessels 1985; 22: 105-126.
21. Cunha R, Dabire H, Bezie I, et al. Mechanical stress of the carotid artery at the early phase of spontaneous hypertension in rats. Hypertension 1997; 29: 992-998.
22. Gardiner SM, March JE, Kemp PA, et al. Haemodynamic effect of the selective phosphodiesterase 5 inhibitor, UK-357,903, in conscious SHR. Brit J Pharmacol 2004; 141: 114-122.
23. Andersen CU, Mulvany MJ, Simonsen U. Lack of synergistic effect of molsidomine and sildenafil on development of pulmonary hypertension in chronic hypoxic rats. Europ J Pharmacol 2005; 510: 87-96.
24. Lepore JJ, Maroo A, Bigatello LM, et al. Haemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension - Combined administration with inhaled nitric oxide. Chest 2005; 127: 1647-1653.
25. Das A, Xi L, Kukreja RC. Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. J Biol Chem 2005; 280: 12944-12955.
26. Mulvany JM. Small artery remodeling and significance in the development of hypertension. News Physiol Sci 2002; 17: 105-109.
27. Glasser SP. Clinical mechanisms of nitrate action. Am J Cardiol 1998; 81: 49A-53A.
28. Fink B, Bassenge E. Unexpected, tolerance-devoid vasomotor and platelet actions of pentaerythrityl tetranitrate. J Cardiovasc Pharmacol 1997; 30: 831-836.
29. Hinz B, Kuntze U, Schröder H. Pentaerythrityl tetranitrate and its phase I metabolites are potent activators of cellular cyclic GMP accumulation. Biochem Biophys Res Commun 1998; 253: 658-661.
30. Halcox JPJ, Nour KRA, Zalos G, et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002; 40: 1232-1240.
31. Grunwald JE, Metelitsina T, Grunwald L. Effect of sildenafil citrate (viagra) on retinal blood diameter. Am J Ophthalmol 2002; 133: 809-812.
32. Kristek F, Gerová M. Myoendothelial relations in the conduit coronary artery of the dog and rabbit. J Vasc Res 1992; 29: 29-32.
33. Kristek F, Gerová M. Dynamics of endothelium-muscle cell contacts in the coronary artery of the dog in ontogeny. Acta Anat 1997; 158: 166-171.
34. Thubrikar MJ, Robicsek F. Pressure-induced arterial-wall stress and atherosclerosis. Ann Thorac Surg 1995; 59: 1594-1603.